戴維醫療(300314.SZ)上修業績預告:前三季淨利預增195%-225%
格隆匯 10 月 14日丨戴維醫療(300314.SZ)發佈2020年前三季度業績預告修正公告,修正後2020年1-9月預計歸屬於上市公司股東的淨利潤1.19億元-1.31億元,比上年同期增長:195%-225%。其中,2020年第三季度預計歸屬於上市公司股東的淨利潤6559.88萬元-7174.87萬元,比上年同期增長:220%-250%。
由於公司財務人員的疏忽,對新會計準則理解不到位,導致公司對參股公司深圳市陽和生物醫藥產業投資有限公司對外投資的南京偉思醫療科技股份有限公司核算的投資收益少計了約1800萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.